Isolation of *Klebsiella pneumoniae* Producing NDM-1 Metallo- β -Lactamase from the Urine of an Outpatient Baby Boy Receiving Antibiotic Prophylaxis

New Delhi metallo- β -lactamase 1 (NDM-1) is a newly described metallo- β -lactamase (MBL) first identified in 2008 in single isolates of *Klebsiella pneumoniae* and *Escherichia coli*, with both recovered from a patient repatriated to Sweden after treatment in a hospital in New Delhi, India (8). Urinary tract infection (UTI) is a very common illness in children (4).

The first patient in Serbia with NDM-1-producing *K. pneumoniae* was a 7-month-old male baby. At the age of 4 months (in April 2011), he was hospitalized in Belgrade for prolonged constipation and suspected megacolon. On examination, the patient was afebrile, and laboratory studies including complete blood indices were normal. During the hospitalization, 10×10^3 CFU/ml *E. coli*, susceptible to antibiotics, was isolated from urine in the absence of leukocyturia. The patient was treated with cephalexin.

In June 2011, a voiding cystourethrogram revealed bilateral vesicoureteral reflux grade II. The patient was afebrile, laboratory studies including C-reactive protein were normal, and there was no leukocyturia. The patient was treated with amoxicillin/clavulanate (50 mg/kg of body weight/day divided every 8 h [q8h]) for 7 days, followed by cephalexin (10 mg/kg as a single daily dose) as an antibiotic prophylactic. In August 2011, 5×10^3 CFU/ml *K. pneumoniae*, named IT977, was isolated from urine. The isolate was resistant (disk diffusion test and Vitek 2) to ampicillin, ampicillin-sulbactam, piperacillin-tazobactam, cefazolin, ceftriaxone, cefepime, aztreonam, ertapenem, imipenem, meropenem, gentamicin, tobramycin, ciprofloxacin, moxifloxacin, nitrofurantoin, and trimethoprim-sulfamethoxazole, was susceptible to tigecycline and fosfomycin, and had intermediate susceptibility to amikacin according to the CLSI guidelines (2). A phenotypic confirmatory disk diffusion test using both cefotaxime and ceftazidime, alone and in combination with clavulanic acid, was negative for extended-spectrum β -lactamase production (2). This isolate was susceptible to colistin (MIC = 0.5 μ g/ml; Etest).

The isolate was positive for MBL production in the imipenem-EDTA, ceftazidime-EDTA, and cefepime-EDTA combined disk tests. The gene *bla*_{NDM-1} was detected using PCR as described previously (5). In order to reveal the *bla*_{NDM-1} gene sequence, a cosmid library of *K. pneumoniae* IT977 total DNA (PstI digested) was constructed (5). Sequencing revealed the presence of the *bla*_{NDM-1} gene located on a 1,059-bp EcoRI fragment (GenBank accession no. HE866523).

To our knowledge, this is the first documented isolation of *Enterobacteriaceae* producing NDM-1 in Serbia. Reports of *Entero-*

bacteriaceae producing NDM-1 in patients who traveled in or originated from Serbia suggest that the Balkans may represent a second reservoir of NDM-1-producing bacteria (6, 7). Jovic et al. reported isolation of a *Pseudomonas aeruginosa* strain producing NDM-1 in patients in the Military Medical Academy, Belgrade, Serbia (5). We did not investigate the other possible mechanisms of resistance to beta-lactam antibiotics in this isolate.

Our patient had no evidence of UTI, and the voiding cystourethrogram revealed bilateral vesicoureteral reflux grade II. He has never had leukocyturia or clinical signs or symptoms of infection, yet he was treated with antibiotics and prescribed antibiotic prophylactics. Some authors found that antimicrobial prophylaxis is associated with an increased risk of resistant infections (1, 3). With *Enterobacteriaceae* acquiring such powerful mechanisms of resistance, there is a need for additional critical review of antibiotic prophylaxis in children such as our patient.

ACKNOWLEDGMENTS

This work was supported by grants 173019 and 175061 from the Ministry of Education and Science of the Republic of Serbia.

REFERENCES

- Cheng CH, et al. 2008. Antibiotic resistance patterns of community-acquired urinary tract infections in children with vesicoureteral reflux receiving prophylactic antibiotic therapy. *Pediatrics* 122:1212–1217.
- Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing. CLSI M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
- Conway PH, et al. 2007. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. *JAMA* 298:179–186.
- Craig JC, et al. 2009. Antibiotic prophylaxis and recurrent urinary tract infection in children. *N. Engl. J. Med.* 361:1748–1759.
- Jovic B, et al. 2011. Emergence of NDM-1 metallo- β -lactamase in *Pseudomonas aeruginosa* clinical isolates from Serbia. *Antimicrob. Agents Chemother.* 55:3929–3931.
- Livermore DM, Walsh TR, Toleman MA, Woodford N. 2011. Balkan NDM-1: escape or transplant? *Lancet Infect. Dis.* 11:164.
- Struelens MJ, et al. 2010. New Delhi metallo-beta-lactamase 1-producing *Enterobacteriaceae*: emergence and response in Europe. *Euro Sur-*

Published ahead of print 20 August 2012

Address correspondence to Veljko Mirovic, ve.mir@sbb.rs.

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.00838-12

- veill. 15(46):pii=19716. <http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19716>.
8. Yong D, et al. 2009. Characterization of a new metallo- β -lactamase gene,

*bla*_{NDM-1}, and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. Antimicrob. Agents Chemother. 53:5046–5054.

Veljko Mirovic

Department for Microbiology
School of Dentistry
University Privredna Akademija
Pančevo, Serbia

Branka Tomanovic

Zorica Lepsanovic

Department for Microbiology and Epidemiology
Military Medical Academy
Belgrade, Serbia

Branko Jovcic

Faculty of Biology
University of Belgrade
Belgrade, Serbia

Milan Kojic

Institute of Molecular Genetics and Genetic Engineering
University of Belgrade
Belgrade, Serbia